Recombinant EGFR (Zalutumumab Biosimilar) antibody
Research Grade
Reactivity: Human
ELISA
Host: Mammalian Cells
Monoclonal
unconjugated
Recombinant Antibody
-
- Target See all EGFR (Zalutumumab Biosimilar) products
- EGFR (Zalutumumab Biosimilar)
- Antibody Type
- Recombinant Antibody
- Reactivity
- Human
-
Host
-
Mammalian Cells
-
Clonality
- Monoclonal
-
Conjugate
- This EGFR (Zalutumumab Biosimilar) antibody is un-conjugated
-
Application
- ELISA
- Purpose
- Zalutumumab Biosimilar - Anti-EGFR mAb
- Characteristics
- Antibody Type: IgG1-kappa
- Grade
- Research Grade
- Isotype
- IgG1 kappa
-
-
- Restrictions
- For Research Use only
-
- Buffer
- PBS pH 7.5
- Storage
- -80 °C
- Storage Comment
- store at -80°C
-
- Target
- EGFR (Zalutumumab Biosimilar)
- Abstract
- EGFR (Zalutumumab Biosimilar) Products
- Synonyms
- ERBB antibody, ERBB1 antibody, HER1 antibody, PIG61 antibody, mENA antibody, epidermal growth factor receptor antibody, EGFR antibody
- Target Type
- Biosimilar
- Background
-
HuMax-EGFr
Zalutumumab (proposed trade name HuMax-EGFR) is a high affinity, completely human IgG1 monoclonal antibody (mAb) directed towards the epidermal growth factor receptor (EGFR, also known as ErbB1/HER1). It is developed by Genmab and designed for the treatment of squamous cell carcinoma of the head and neck (SCCHN), a type of cancer. Zalutumumab is derived from transgenic mice immunized with A431-derived EGFR. - CAS-No
- 667901-13-5
-
You are here:
